DPP1 inhibitor
Insmed Delivers Rare Disappointment as Brinsupri Flops in Mid-Stage Rhinosinusitis Study
Insmed; Brensocatib; Brinsupri; DPP1 inhibitor; chronic rhinosinusitis without nasal polyps; mid-stage trial; Phase 2b; nasal inflammation; trial failure; biotech stocks; INS1148 acquisition